Article Information
History
- April 6, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Jun Fei1,†,
- Lin Fu1,2,†,
- Ying Li3,†,
- Hui-Xian Xiang1,
- Ying Xiang1,
- Meng-Die Li1,
- Fang-Fang Liu1,
- De-Xiang Xu2,* and
- Hui Zhao1,*
- 1Second Affiliated Hospital, Anhui Medical University, Hefei, Anhui Province, 230032, China
- 2Department of Toxicology, Anhui Medical University, Hefei, Anhui Province, 230032, China
- 3Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, 430040, China
- ↵*Corresponding author:
Professor Hui Zhao, Professor De-Xiang Xu, Anhui Medical University, 81 Meishan Road, Hefei City, 230 032, Anhui Province, China, Phone: 86 (551) 65167923, E-mail:
zhaohuichenxi{at}126.com (H. Zhao); xudex{at}126.com (D.-X. Xu).
↵† These authors contributed equally to this work.
Posted April 06, 2020.
Reduction of lymphocyte at early stage elevates severity and death risk of COVID-19 patients: a hospital-based case-cohort study
